Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania

Behavioural Pharmacology

Volumn 17, Issue 4, 2006, Pages 311-318

  Frey, Benício N ^a,b   Andreazza, Ana C ^a,b   Rosa, Adriane R ^b   Martins, Márcio R ^c   Valvassori, Samira S ^c   Réus, Gislaine Z ^c   Hatch, John P ^d,e   Quevedo, João ^c   Kapczinski, Flávio ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Amphetamine; Animal model; Lithium; Mania; Nerve growth factor; Rat; Valproate

Indexed keywords

AMPHETAMINE; LITHIUM; MOOD STABILIZER; NERVE GROWTH FACTOR; NEUROTROPHIN; PROTEIN TYROSINE KINASE A; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; HYPERACTIVITY; LOCOMOTION; MALE; MANIA; MOOD; NONHUMAN; OPEN FIELD BEHAVIOR; PATHOPHYSIOLOGY; RAT;

AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; HIPPOCAMPUS; LITHIUM; MALE; MOTOR ACTIVITY; NERVE GROWTH FACTORS; RATS; RATS, WISTAR; VALPROIC ACID;

EID: 33747475674     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000205013.59455.09     Document Type: Article

References (37)

1. Altar CA (1999). Neurotrophins and depression. Trends Pharmacol Sci 202: 59-61.
2. Angelucci F, Aloe L, Gruber SH, Fiore M, Mathe AA (2000). Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int J Neuropsychopharmacol 3:13-25.
3. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA (2003a). Electroconvulsive stimuli alter nerve growth factor but not brain-derived neurotrophic factor concentrations in brains of a rat model of depression. Neuropeptides 37: 51-56.
4. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA (2003b). Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 6:225-231.
5. Atwal JK, Massie B, Miller FD, Kaplan DR (2000). The TrkB-Shc site signals neuronal survival and local axon growth via MEK and PI3-kinase. Neuron 27:265-277.
6. Belmaker RH (2004). Bipolar disorder. N Engl J Med 351:476-486.
7. Bersani G, Iannitelli A, Maselli P, Pancheri P, Aloe L, Angelucci F, Alleva E (1999). Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr Res 37:201-203.
8. Bezchlibnyk Y, Young LT (2002). The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 47:135-148.
9. Black IB (1999). Trophic regulation of synaptic plasticity. J Neurobiol 41: 108-118.
10. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000). Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75:1729-1734.
11. Craddock N, O'Donovan MC, Owen MJ (2005). The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 42:193-204.
12. Duman RS (2002). Synaptic plasticity and mood disorders. Mol Psychiatry 7(Suppl 1):S29-S34.
13. Einat H, Kofman O, Belmaker RH (2000). Animal models of bipolar disorder: from a single episode to progressive cycling models. In: Myslobodsky M, Weiner I, editors. Contemporary issues in modeling psychopathology. Boston: Kluwer Academic Publishers. pp. 165-180.
14. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, et al. (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23:7311-7316.
15. Finkbeiner S (2000). CREB couples neurotrophin signals to survival messages. Neuron 25:11-14.
16. Follesa P, Gale K, Mocchetti I (1994). Regional and temporal pattern of expression of nerve growth factor and basic fibroblast growth factor mRNA in rat brain following electroconvulsive shock. Exp Neurol 127:37-44.
17. Frazier JA, Schiu S, Breeze JL, Makris N, Lange N, Kennedy DN, et al. (2005). Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry 162:1256-1265.
18. Frey BN, Andreazza AC, Ceresér KMM, Martins MR, Valvassori SS, Réus GZ, et al. (2006). Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci (in press).
19. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berlin) 158:100-106.
20. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P (2001). BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411:86-89.
21. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002). Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43:1173-1179.
22. Hashimoto K, Shimizu E, Iyo M (2004). Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45:104-114.
23. Hellweg R, Lang UE, Nagel M, Baumgartner A (2002). Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 7:604-608.
24. Jockers-Scherubl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R (2003). Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 17: 439-445.
25. Machado-Vieira R, Kapczinski F, Soares JC (2004). Perspectives for the development of animal models of bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 28:209-224.
26. Manji HK, Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nat Med 7:541-547.
27. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000). Lithium-induced increase in human brain grey matter. Lancet 356:1241-1242.
28. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T (2003). Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119:767-775.
29. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547.
30. Nibuya M, Nestler EJ, Duman RS (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365-2372.
31. Pantazopoulos H, Stone D, Walsh J, Benes FM (2004). Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 54:147-155.
32. Parikh V, Evans DR, Khan MM, Mahadik SP (2003). Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 60:117-123.
33. Rajkowska G (2003). Depression: what we can learn from postmortem studies? Neuroscientist 9:273-284.
34. Sassi RB, Nicoletti M, Brambilla P, Mallinger AG, Frank E, Kupfer DJ, et al. (2002). Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 329:243-245.
35. Soares JC, Mann JJ (1997). The functional neuroanatomy of mood disorders. J Psychiatr Res 31:393-432.
36. Vogel M, Pfeifer S, Schaub RT, Grabe HJ, Barnow S, Freyberger HJ, Cascorbi I (2004). Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50:305-310.
37. Yetnikoff L, Arvanitogiannis A (2005). A role for affect in context-dependent sensitization to amphetamine. Behav Neurosci 119:1678-1681.